Skip to content

Adapting FAMS to Optimize CGM Use Among Emerging Adults With Type 1 Diabetes

Adapting FAMS to Optimize CGM Use Among Emerging Adults With Type 1 Diabetes

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05854069
Enrollment
140
Registered
2023-05-11
Start date
2023-04-30
Completion date
2027-04-30
Last updated
2025-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Keywords

Continuous glucose monitor, Social support, Goal setting, Diabetes distress, Hemoglobin A1c, Time in range, Emerging adults, Family support, Text message, Mobile health

Brief summary

The goal of this clinical trial is to evaluate the efficacy of an adapted FAMS (Family/friend Activation to Motivate Self-care) intervention on CGM use among study participants who are CGM users. We will leverage the infrastructure of an NIDDK-funded RCT evaluating FAMS-T1D among N=280 emerging adults with T1D who have elevated hemoglobin A1c or elevated diabetes distress (NCT05820477). We anticipate at least 50% using CGM to be included in these analyses.

Detailed description

FAMS (Family/friend Activation to Motivate Self-care) is a mobile phone-delivered intervention, based on Family Systems Theory, which helps adults with diabetes set behavioral goals and improve support received from friends and family for goal success. FAMS includes monthly phone coaching and text message support by FAMS coaches for the person with diabetes (PWD) and the option to enroll a support person (SP) to receive automated texts tailored to the self-care goals the person with T1D sets in coaching sessions. Adaptations specific to CGM include the option to set CGM use goals in coaching (and receive associated text support) and skill-building exercises during coaching to support data sharing relationships (e.g., establishing, setting and adjusting ground rules about communication). Within the FAMS-T1D RCT (NCT05820477), we will test effects of FAMS-T1D on CGM use use relative to enhanced treatment as usual. We will evaluate effects on CGM use from baseline to post-intervention (6 months) as the primary endpoint. Study start date for the nested trial (NCT05854069) is the enrollment date of the first participant using a CGM. Since the goal of this trial is to assess effects of the adapted FAMS intervention on CGM use, the date participant CGM usage was confirmed is considered the enrollment date.

Interventions

BEHAVIORALFAMS-T1D

FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled. Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly.

Quality digital resources about diabetes management provided upon enrollment and during the study.

Sponsors

The Leona M. and Harry B. Helmsley Charitable Trust
CollaboratorOTHER
University of Utah
CollaboratorOTHER
University of California, Merced
CollaboratorOTHER
Children's Hospital Los Angeles
CollaboratorOTHER
Vanderbilt University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 24 Years
Healthy volunteers
No

Inclusion criteria

PERSONS WITH DIABETES * Ages 18-24 * Have a diagnosis of T1D and has been taking insulin for at least one year * Comfortable sending and receiving texts * Can speak, read, and write in English * Meets one of the following two criteria: 1) has a most recent A1c value in the EHR that is 7.5% or higher (or missing) OR 2) screen positive for diabetes distress on the two-item Diabetes Distress Screen (DDS-2) * Using a continuous glucose monitor (CGM) SUPPORT PERSONS * Age 18 or older * Can speak, read, and write in English or Spanish * Comfortable sending and receiving texts

Exclusion criteria

PERSONS WITH DIABETES * Has a condition that would prohibit study completion (intellectual disability, blindness or auditory limitations, severe mental illness) * Plans to live outside the country during the study period SUPPORT PERSONS * Shares a phone with the person with diabetes * Plans to live outside of the country during the study period

Design outcomes

Primary

MeasureTime frameDescription
CGM frequency of use during the intervention periodBaseline and 6 months post-baselineChange in CGM frequency of use assessed by self-report on questionnaire; more frequent use/higher is better
Gaps in CGM use6 months post-baselineLength of gaps in CGM use as assessed by objective CGM data (measured in number of consecutive days without CGM data; higher is worse)

Secondary

MeasureTime frameDescription
CGM satisfaction during the intervention periodBaseline and 6 months post-baselineChange in CGM satisfaction assessed by Benefits of CGM scale; higher scores indicate more perceived benefits of CGM use (better)
Barriers to CGM use during the intervention periodBaseline and 6 months post-baselineChange in perceived influence of CGM on glycemic control scale assessed by Glucose Monitoring Survey; higher scores indicate more perceived problems with CGM use (worse)
CGM behavioral responses during the intervention periodBaseline and 6 months post-baselineChange in frequency of making behavioral changes in response to CGM data assessed by self-report; higher scores indicate more frequent response (better)

Other

MeasureTime frameDescription
Data sharing during the intervention period6 months post-baselineNumber of data sharing relationships, between groups; more is better
Satisfaction with data-sharing relationships6 months post-baselineSatisfaction with data-sharing relationships assessed by CGM-Satisfaction Scale; higher scores are better

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026